Core Insights - LENSAR Inc. is a key player in the medical technology sector, specializing in robotic laser solutions for cataract treatment, with quarterly earnings expected on March 19, 2026, projecting an EPS of approximately -$0.06 and revenue around $20.3 million [1][6] Financial Performance - The company experienced a stock decline following the termination of its merger agreement with Alcon AG, which was initially valued at about $356 million at $14.00 per share [2] - LENSAR retains a $10 million deposit from the canceled merger, but faces financial challenges indicated by a negative P/E ratio of -1.66 and a negative earnings yield of -60.17%, suggesting it is currently not profitable [3][6] - The price-to-sales ratio is approximately 1.44, indicating investors pay $1.44 for every dollar of sales, while the enterprise value to sales ratio is about 1.36 [4] - The enterprise value to operating cash flow ratio stands at -6.80, highlighting ongoing financial difficulties [4] - Despite these challenges, LENSAR maintains a current ratio of 1.24, indicating sufficient current assets to cover current liabilities [5][6] - The company has a debt-to-equity ratio of -0.24, suggesting it has more liabilities than equity [5]